Reduced expression levels of PTEN are associated with decreased sensitivity of HCC827 cells to icotinib

YANG ZHAI1, YANJUN ZHANG1, KEJUN NAN2 and XUAN LIANG2

1Department of Oncology, Tumor Hospital of Shaanxi Province; 2Department of Oncology, First Affiliated Hospital, Xi’an Jiaotong University Medical College, Xi’an, Shaanxi 710061, P.R. China

Received July 22, 2015; Accepted September 9, 2016

DOI: 10.3892/ol.2017.5829

Abstract. The clinical resistance of non-small cell lung cancer (NSCLC) to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been linked to EGFR T790M resistance mutations or MET amplifications. Additional mechanisms underlying EGFR-TKI drug resistance remain unclear. The present study demonstrated that icotinib significantly inhibited the proliferation and increased the apoptosis rate of HCC827 cells; the cellular mRNA and protein expression levels of phosphatase and tensin homolog (PTEN) were also significantly downregulated. To investigate the effect of PTEN expression levels on the sensitivity of HCC827 cells to icotinib, PTEN expression was silenced using a PTEN-specific small interfering RNA. The current study identified that the downregulation of PTEN expression levels may promote cellular proliferation in addition to decreasing the apoptosis of HCC827 cells, and may reduce the sensitivity of HCC827 cells to icotinib. These results suggested that reduced PTEN expression levels were associated with the decreased sensitivity of HCC827 cells to icotinib. Furthermore, PTEN expression levels may be a useful marker for predicting icotinib resistance and elucidating the resistance mechanisms underlying EGFR-mutated NSCLC.

Introduction

Lung cancer is one of the most common malignant tumors with the highest morbidity and mortality, and non-small cell lung cancer (NSCLC) accounts for >80% of the recorded cases (1). Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), including gefitinib, are tumor-molecular-targeted agents, which have become an important therapeutic strategy for NSCLC (2). Icotinib hydrochloride (icotinib) was developed in China, and is a highly selective first-generation EGFR-TKI (3). Icotinib is indicated for the treatment of EGFR mutation-positive, advanced or metastatic NSCLC, or as a second- or third-line treatment (3). However, the majority of patients with NSCLC develop an acquired resistance to EGFR-TKIs 8-10 months following the initiation of treatment (2,4). It has been previously demonstrated that a second point mutation on EGFR in exon 20 (T790 M) and a MET gene amplification underlie the development of an acquired resistance to EGFR-TKIs in patients with NSCLC (5-8). However, the mechanisms underlying acquired resistance are not determined for ~30% of cases (5).

Phosphatase and tensin homolog (PTEN; deleted on chromosome 10) is a tumor-suppressor gene that has dual-specificity phosphatase activity (9). PTEN is mutated in various types of human cancer and regulates cellular growth using hyper-phosphorylation and dephosphorylation (10). PTEN may be involved in the infiltration and migration of tumor cells and may affect vessel formation (11). The tumorigenesis of lung cancer is a complex biological process; the present study identified that PTEN is inactivated and abnormally expressed in lung cancer (11). It was hypothesized that the loss of PTEN expression may contribute to the development of EGFR-TKI resistance in EGFR mutation-positive NSCLC. In the current study, the effect of icotinib on HCC827 cells and the association between PTEN expression levels and cell sensitivity to icotinib was evaluated; gene expression levels and the biological behavior of HCC827 cells was also investigated for each group. The aim of the present study was to elucidate the mechanisms underlying acquired resistance to EGFR-TKIs.

Materials and methods

Cell culture and reagents. The HCC827 NSCLC cell line was provided by Xi’an Jiaotong University (Xi’an, China); the HCC827 cells had an acquired E746-A750 deletion mutation in the EGFR tyrosine kinase domain. The cells were cultured in RPMI-1640 (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) supplemented with 20% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 37°C in an atmosphere containing 5% CO2. Icotinib was purchased from Zhejiang Beida Pharmaceutical Co., Ltd.

Correspondence to: Professor Kejun Nan or Dr Xuan Liang, Department of Oncology, First Affiliated Hospital, Xi’an Jiaotong University Medical College, 277 Yanta West, Yanta, Xi’an, Shaanxi 710061, P.R. China
E-mail: nankj1958@163.com
E-mail: liangxuan029@163.com

Key words: non-small cell lung cancer, HCC827 cells, icotinib, phosphatase and tensin homolog, small interfering RNA
(Beijing, China). MTT, dimethyl sulfoxide (DMSO), and propidium iodide (PI) were purchased from Sigma-Aldrich (Merck Millipore, Darmstadt, Germany). Anti-PTEN (#9552; dilution, 1:2,000) was purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). Horseradish peroxidase-conjugated AffiniPure goat anti-rabbit immunoglobulin G (H+L; #AP60720; dilution, 1:2,000) was obtained from Abgent Biotech Co., Ltd. (Suzhou, China) and the anti-β-actin antibody (#sc-130300; dilution, 1:1,500) was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA).

PTEN-small interfering (si)RNA design, synthesis and transfection. siRNAs corresponding to PTEN (upstream, 5'-GAUAAGACAACACGCCAAGTT-3'; downstream, 5'-CUUGAGGCUGUUAGCAUCTT-3') were purchased from Shanghai GenePharma Co., Ltd. (Shanghai, China). The cells were plated in culture plates in RPMI-1640 (HyClone; GE Healthcare Life Sciences, Logan, UT, USA) supplemented with 20% fetal bovine serum at 37°C. Following the transfection reagents, the transfection medium was replaced with RPMI-1640 supplemented with 20% FBS. The cells were then incubated at 37°C for 24-48 h in 5% CO₂. Two wells were left untransfected to serve as a negative control.

Drugs and growth-inhibition assay. Cells were seeded at a density of 2-4 × 10⁴/100 µl in 96-well plates and incubated at 37°C overnight in 5% CO₂. Subsequently, various concentrations (0.5 nM/µl, 1 nM/µl, 2 nM/µl, 4 nM/µl, 8 nM/µl) of icotinib were added; following incubation times of 24, 48 and 72 h at 37°C, 20 µl MTT (5 mg/ml) was added to each well and the plates were incubated for 4 h at 37°C. Then, 150 µl DMSO was oscillated for 10 min and the absorbance was measured at 490 nm with a 96-well plate reader (Health, Bethesda, MA, USA). The total RNA (1,248.52 ng/µl) from cells was extracted using RNA Fast200 (Sigma-Aldrich; Merck Millipore). The PCR amplification reaction mixture (10 µl) contained the following: 5°PrimeScript buffer (2 µl), PrimeScript RT enzyme mix (0.5 µl), oligo dT primer (0.5 µl), random hexanucleotide (0.5 µl), total RNA (4 µl) and RNase Free (Takara Bio, Inc., Otsu, Japan). The thermal cycler conditions were as follows: 94°C for 2 min then 35 cycles alternating between 94°C for 30 sec, 60°C for 30 sec, 72°C for 30 sec and 72°C for 2 min. The target gene expression levels were normalized to GAPDH levels. The formula 2^(-ΔΔCq)=2^[-Cq (GAPDH)-Cq(target)] was used to calculate the relative gene expression levels for each sample, reflecting the normalized target gene expression levels. The primer sequences were as follows: Upstream, 5'-CTATTTCCCCAGTC AGAGGCGCTAT-3'; downstream, 5'-TGACTTGTCTT CCCGTCGTT-3'.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The total RNA (1,248.52 ng/µl) from cells was extracted using RNA Fast200 (Sigma-Aldrich; Merck Millipore). The PCR amplification reaction mixture (10 µl) contained the following: 5°PrimeScript buffer (2 µl), PrimeScript RT enzyme mix (0.5 µl), oligo dT primer (0.5 µl), random hexanucleotide (0.5 µl), total RNA (4 µl) and RNase Free (Takara Bio, Inc., Otsu, Japan). The thermal cycler conditions were as follows: 94°C for 2 min then 35 cycles alternating between 94°C for 30 sec, 60°C for 30 sec, 72°C for 30 sec and 72°C for 2 min. The target gene expression levels were normalized to GAPDH levels. The formula 2^(-ΔΔCq)=2^[-Cq (GAPDH)-Cq(target)] was used to calculate the relative gene expression levels for each sample, reflecting the normalized target gene expression levels. The primer sequences were as follows: Upstream, 5'-CTATTTCCCCAGTC AGAGGCGCTAT-3'; downstream, 5'-TGACTTGTCTT CCCGTCGTT-3'.

Statistical analysis. The data are presented as the mean ± standard deviation. The data were analyzed using SPSS version 17.0 software (SPSS, Inc., Chicago, IL, USA). Statistical analysis was conducted using an independent t-test. P<0.05 was considered to indicate a statistically significant difference.
Results

**Icotinib inhibited the growth of HCC827 cells.** To study the effects of icotinib on HCC827 lung cancer cells, an MTT assay was used to test cell growth and survival (Fig. 1). The present study identified that icotinib induces damage to HCC827 cells, which was enhanced with increasing time and concentration (P<0.001).

**Icotinib inhibits cell apoptosis and the cell cycle of HCC827 cells.** As indicated in Fig. 2, treatment with icotinib significantly inhibited the proliferation and increased the rate of apoptosis of HCC827 cells (P<0.001; Fig. 2A and B). The number of cells in the G₀/G₁ cell cycle phase was increased following treatment with icotinib, compared with the control group, suggesting that icotinib significantly attenuated the cell cycle in the G₀/G₁ phase (P<0.001; Fig. 2C and D).

**Icotinib downregulates PTEN expression.** To investigate the association between icotinib and its relevant effects, the expression levels of PTEN were examined using RT-qPCR and western blotting (Fig. 3A and B). The RT-qPCR results revealed that PTEN mRNA expression levels were decreased by ~34% following treatment with icotinib (P<0.001; Fig. 3C). The results of the western blotting demonstrated that the protein expression levels of PTEN in the HCC827 cells were significantly downregulated (P<0.001; Fig. 3D).

**PTEN in HCC827 cells is downregulated by transient transfection.** To evaluate the effects of the downregulation of PTEN expression in HCC827 cells, the cells were transfected with an siRNA corresponding to PTEN. To determine whether PTEN expression in HCC827 cells was downregulated, RT-qPCR and western blotting were used to analyze the PTEN expression levels in each group (Fig. 4A and B). RT-qPCR demonstrated that PTEN expression levels decreased by ~52% following transfection, suggesting that PTEN was significantly downregulated by PTEN-siRNA (P<0.001; Fig. 4C). The protein expression levels of PTEN in the HCC827 cells were significantly decreased following transfection with the PTEN siRNA, as compared with the control (P<0.001; Fig. 4D).

Silencing PTEN expression promotes the growth of HCC827 cells. An MTT assay was used to examine cell growth in each
Reduced expression levels of PTEN are associated with decreased sensitivity

In the HCC827/PTEN-NC and HCC827/PTEN-siRNA cells, we observed a decrease in PTEN expression levels by ~52% following transfection, suggesting that PTEN was successfully downregulated by PTEN-siRNA. Western blotting further confirmed that PTEN protein expression was also significantly downregulated (*P<0.05). GAPDH or β-actin was used as a control for sample loading. *P<0.05, vs. the control. PTEN, phosphatase and tensin homolog; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NC, negative control; siRNA, small-interfering RNA.

Figure 4. PTEN expression in HCC827 cells was successfully downregulated by PTEN-siRNA. (A and B) The PTEN mRNA and protein expression levels in the HCC82, HCC827/PTEN-NC and HCC827/PTEN-siRNA cells were detected using RT-qPCR and western blotting, respectively. (C) RT-qPCR revealed that PTEN expression levels were decreased by ~52% following transfection, suggesting that PTEN was successfully downregulated by PTEN-siRNA. (D) Western blotting demonstrating that PTEN protein expression was also significantly downregulated (*P<0.05). GAPDH or β-actin was used as a control for sample loading. *P<0.05, vs. the control. PTEN, phosphatase and tensin homolog; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NC, negative control; siRNA, small-interfering RNA.

Figure 5. The cell growth curve for each group. A cell growth curve presents the absorbance values with the ordinate and time as abscissas. Data are presented as the mean ± standard deviation from three independent experiments. PTEN, phosphatase and tensin homolog; NC, negative control; siRNA, small-interfering RNA.

group, as indicated in Fig. 5; the growth of HCC827 cells was observed to be inhibited by icotinib treatment (P=0.0042). However, the growth of HCC827 cells was promoted if the PTEN gene was silenced (P=0.0117).

Silencing PTEN expression decreases the apoptosis of HCC827 cells. Transfection with PTEN siRNA decreased the rate of apoptosis of HCC827 cells, compared with the control group (P<0.001). Concordant with the previous results, the number of cells in the G0/G1 phase was increased following icotinib treatment (P<0.001) and no significant difference was observed between the control and PTEN-siRNA groups (Fig. 6).

Silencing PTEN expression decreases the sensitivity of HCC827 cells to icotinib. In the HCC827 cells transfected with PTEN siRNA, the inhibition rate of icotinib was significantly decreased, compared with the control group, and the IC50 was significantly increased (22.52 nmol) following transfection (P<0.001; Fig. 7).

Discussion

Icotinib hydrochloride is an EGFR-TKI that targets the mutated EGFR gene (3). If ligands including epidermal growth factor, transforming growth factor or amphiregulin are combined with the extracellular domain of EGFR, the
intracellular tyrosine kinase may be activated and combine with adenosine triphosphate (ATP) (12). The phosphorylation of ATP activates downstream signal transduction pathways, including the rat sarcoma (RAS)/mitogen-activated protein kinases (MAPK), phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/protein kinase B (Akt) and proto-oncogene tyrosine-protein kinase Src signaling pathway, which may induce tumor cell proliferation, anti-apoptosis, invasion and metastasis (5).

It has previously been reported that EGFR-TKIs may suppress tumor growth by binding to the intracellular domain (magnesium-ATP) of EGFR, which may inhibit the activity and phosphorylation of the tyrosine kinase and block downstream signal transduction pathways (12). However, the majority of patients with NSCLC develop an acquired resistance to EGFR-TKIs within 8-10 months (13). A previous study on TKI-sensitive NSCLC indicated that a mutation in the EGFR tyrosine kinase domain is responsible for activating various anti-apoptotic signaling pathways (14). An EGFR mutation may be detected in 43-89% of patients with lung cancer; mutations on exons 19 and 21 are the most common (15). These mutations have been observed to confer increased cell sensitivity to TKIs, including to icotinib (3). In addition to a second point mutation in EGFR on exon 20 (T790M) and a MET gene amplification, Kirsten-RAS, PIK3, insulin-like growth factor-1 and epithelial-mesenchymal transition target gene amplification mutations are also associated with acquired resistance to EGFR-TKIs (13,14,16).

Similar to other EGFR-TKIs, icotinib may induce cell proliferation inhibition, cell apoptosis and cell cycle arrest by inhibiting the activity and phosphorylation of the tyrosine kinase domain (3). The current study identified that icotinib may damage HCC827 cells in a time- and concentration-dependent manner. Treatment with icotinib significantly inhibited the proliferation and increased the rate of apoptosis of HCC827 cells, in which the mRNA and protein expression levels of PTEN were significantly downregulated. The PTEN gene is a tumor suppressor gene located on chromosome 10q23.3 (1). PTEN exerts its tumor-suppressing effects through its phosphatase domain and C2 domain (17). It may inhibit phosphatidylinositol (3,4,5)-trisphosphate phosphorylation by specifically antagonizing the PI3K/Akt signaling pathway and suppressing Akt expression, which may induce the apoptosis of Akt-dependent cells (17-21).

A previous study has reported that alterations in PTEN in NSCLC cell lines are associated with a loss of heterozygosity, or with gene deletion (22). Loss of PTEN is involved in the development of EGFR inhibitor resistance in certain tumor cell lines (23,24) and in patients with glioblastoma (25). The underlying mechanisms may include promoter hypermethylation, post-translational modifications or the alternative splicing of the pre-mRNA (26).

PTEN expression patterns in NSCLC require further study, and the role of PTEN in icotinib treatment in NSCLC has yet to be fully elucidated. Yamamoto et al (22) constructed a PC-9/GR EGFR-TKI resistant cell line, and identified that its PTEN expression levels were significantly decreased, and phosphorylated Akt levels were significantly increased. In the present study, it was identified that PTEN mRNA and protein expression levels were significantly downregulated following icotinib treatment. Silencing PTEN expression may promote cell proliferation, decrease the rate of apoptosis of HCC827 cells and reduce the sensitivity of HCC827 cells to icotinib. The current study hypothesized that the underlying mechanisms may involve the loss of PTEN with an increasing PIP-3 concentration, the hyperactivation of Akt and the subsequent release of cytochrome c and the inactivation of forkhead, caspase-9 and B-cell-lymphoma-2 associated agonist of cell death (26). PTEN may influence cell proliferation and apoptosis by regulating the MAPK signaling pathway and the extracellular signal-regulated protein kinase cell survival pathway (22,27,28).

In conclusion, the present study identified that PTEN expression levels affected the sensitivity of HCC827 cells to icotinib treatment, indicating that PTEN may be involved in regulating the icotinib-induced cytotoxicity of HCC827 cells. These results suggest that PTEN may serve as a novel target for monitoring the sensitivity of NSCLC cells to EGFR-TKIs, including icotinib in patients with lung cancer.

References
Cancer non‑small cell lung cancer patients with gefitinib therapy
PTEN and PIK3CA gene copy numbers and poor outcomes in
Batus M, Jacobson KK, Jewell SS, Coon J IV and Bonomi PD:
Fidler MJ, Morrison LE, Basu S, Cell line
cell population, proliferation and senescence in a glioblastoma
and Stat3 signaling regulated by PTEN control of the cancer stem
Leslie NR and Downes CP: PTEN function: How normal cells
Chalhoub N and Baker SJ: PTEN and the PI3 -kinase pathway in
PI
cells by coordinately decreasing MMP expression via the
and Lu CX: TIMP-3K
and Lu CX: PTEN inhibits the migration and invasion of HepG2
cells by coordinately decreasing MMP expression via the
Chalhoub N and Baker SJ: PTEN and the PI3-kinase pathway in
Leslie NR and Downes CP: PTEN function: How normal cells
Moon SH, Kim DK, Cha Y, Jeon I, Song J and Park KS: PI3K/Akt
and Stat3 signaling regulated by PTEN control of the cancer stem
cell population, proliferation and senescence in a glioblastoma
Fidler MJ, Morrison LE, Basu S, Buckingham L, Walters K,
Batus M, Jacobson KK, Jewell SS, Coon J IV and Bonomi PD:
PTEN and PIK3CA gene copy numbers and poor outcomes in
non-small cell lung cancer patients with gefitinib therapy. Br J

Kris MG, Miller VA, Ladanyi M and Riely GJ: Analysis of
tumor specimens at the time of acquired resistance to EGFR-TKI
therapy in 155 patients with EGFR-mutant lung cancers. Clin
14. Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M,
Barrow D, Knowlden JM, Williams S, Wakeling AE and
Nicholson RJ: Insulin-like growth factor-I receptor signalling
and acquired resistance to gefitinib (ZD1839; Iressa) in human
breast and prostate cancer cells. Endocr Relat Cancer 11:
15. Boch C, Kollmeier J, Roth A, Stephan-Falkenau S, Misch D,
Grüning W, Bauer TT and Mairinger T: The frequency of EGFR
and KRAS mutations in non-small cell lung cancer (NSCLC):
Routine screening data for central Europe from a cohort study.
16. Ma C, Wei S and Song Y: T790M and acquired resistance of
EGFR TKI: A literature review of clinical reports. J Thorac
Dis 3: 10-18, 2011.
and Lu CX: PTEN inhibits the migration and invasion of HepG2
cells by coordinately decreasing MMP expression via the
Chalhoub N and Baker SJ: PTEN and the PI3-kinase pathway in
Leslie NR and Downes CP: PTEN function: How normal cells
Moon SH, Kim DK, Cha Y, Jeon I, Song J and Park KS: PI3K/Akt
and Stat3 signaling regulated by PTEN control of the cancer stem
cell population, proliferation and senescence in a glioblastoma
Fidler MJ, Morrison LE, Basu S, Buckingham L, Walters K,
Batus M, Jacobson KK, Jewell SS, Coon J IV and Bonomi PD:
PTEN and PIK3CA gene copy numbers and poor outcomes in
non-small cell lung cancer patients with gefitinib therapy. Br J
22. Yamamoto C, Basaki Y, Kawahara A, Nakashima K, Kage M,
Izumi H, Kohno K, Uramoto H, Yasumoto K, Kuwano M and
Ono M: Loss of PTEN expression by blocking nuclear transloca-
tion of EGR1 in gefitinib-resistant lung cancer cells harboring
epidermal growth factor receptor-activating mutations. Cancer
23. Yamasaki F, Johansen MJ, Zhang D, Krishnamurthy S,
Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K, Mills GB,
Hortobagyi GN and Ueno NT: Acquired resistance to erlotinib
in A-431 epidermoid cancer cells requires down-regulation
of MMAC1/PTEN and up-regulation of phosphorylated Akt.
24. She QB, Solit DB, Ye Q, O'Reilly KE, Lobo J and Rosen N: The
BAD protein integrates survival signaling by EGFR/MAPK
and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.
25. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S,
Dya EQ, Lu KV, Yoshimoto K, Huang HJ and Chute DJ: Molecular
determinants of the response of glioblastomas to EGFR
Zhou CC: MicroRNA-214 Regulates the Acquired Resistance to
Gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.
27. Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T,
contributes to erlotinib resistance in EGFR-mutant lung cancer
by activation of Akt and EGFR. Cancer Res 69: 3256-3261,
2009.
28. Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R,
phoinositide-3-kinase catalytic alpha and KRAS mutations are
important predictors of resistance to therapy with epidermal
growth factor receptor tyrosine kinase inhibitors in patients with
2011.